Ipsen and MD Anderson Announce Bench-to-Bedside Cancer Drug Development Partnership

Ipsen, a global biopharmaceutical group, and The University of Texas MD Anderson Cancer Center today announced a global licensing and joint development agreement for a pre-clinical oncology drug candidate discovered by researchers in MD Anderson ’s Institute for Applied Cancer Science (IACS).06/27/2018
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news